How to Self-Inject Trulicity (Dulaglutide): Step-by-Step Technique, Tips, and Troubleshooting

How the Trulicity Pen Works: Anatomy and Mechanism

The Trulicity autoinjector was designed to remove the barriers that make patients avoid injectable medications. Unlike conventional syringe-and-vial setups, the pen arrives pre-filled with a single, fixed dose. There is no reconstitution, no air-bubble purging, and no dose-dial selection.

The pen body contains four functional zones. At the top sits a clear base cap that locks the device during storage. Below that, a gray button initiates injection when the pen is pressed against skin. The medication window on the barrel lets you confirm the solution is clear and colorless before use. At the bottom, the spring-loaded needle assembly houses a 29-gauge, 5 mm needle that extends only during injection and automatically retracts when the pen is lifted away 1.

A 2019 human-factors study published in Current Medical Research and Opinion found that 99% of participants (N=214) across varying age groups, dexterity levels, and injection experience successfully completed the Trulicity injection on first attempt using the autoinjector without formal training beyond the printed instructions for use 2. That error rate compares favorably to conventional pen injectors, which show first-attempt failure rates between 10% and 16% in real-world audits.

The hidden-needle design addresses a specific clinical problem. Needle phobia affects an estimated 22% of the adult population according to a meta-analysis in the Journal of Advanced Nursing 3, and in patients with type 2 diabetes it has been identified as the primary reason for refusing or delaying injectable therapy in up to 33% of cases.

Step-by-Step Self-Injection Instructions

Follow these seven steps exactly. The entire process takes roughly 30 seconds.

Step 1: Inspect the pen. Remove the pen from refrigeration. Check the expiration date on the label. Look through the medication window to confirm the liquid is clear, colorless to slightly yellow, and free of particles. Do not use a pen that has been frozen or that contains visible clumps.

Step 2: Let the pen reach room temperature. Leave the pen at room temperature for 30 minutes. Injecting cold medication increases discomfort at the site. According to the FDA-approved prescribing information, Trulicity may be stored at room temperature (up to 30°C / 86°F) for up to 14 days 1.

Step 3: Select and clean the injection site. Choose one of three approved areas: the abdomen (at least 2 inches from the navel), the front of the thigh, or the back of the upper arm (this site requires assistance). Clean the skin with an alcohol swab and allow it to air-dry completely. Do not blow on the site.

Step 4: Remove the base cap. Pull the clear base cap straight off. Do not twist it. Once the cap is removed, the green reveal indicator should be visible at the bottom of the pen. You must inject within 72 hours of removing the cap or discard the pen.

Step 5: Place and press. Hold the pen with the gray button on top. Place the clear base flat against your skin. Press the pen firmly against the skin. You will hear a loud click. This is normal. The click indicates the needle has extended and injection has started.

Step 6: Hold for 10 seconds. Keep the pen pressed against your skin. Do not lift or tilt the pen. Count slowly to 10. You will hear a second click when the injection is complete, and the gray button will lock into the down position.

Step 7: Remove and dispose. Lift the pen straight away from the skin. The needle retracts automatically. Place the used pen in an FDA-cleared sharps container. Never recap or reuse the pen 1.

A small drop of blood or medication at the injection site is common. Press gently with a cotton ball. Do not rub.

Injection Site Selection and Rotation

Site rotation prevents lipohypertrophy, a localized accumulation of subcutaneous fat that can impair drug absorption by up to 25%, according to a 2016 study in Diabetes Technology & Therapeutics 4. This is not a cosmetic concern. Injecting repeatedly into hypertrophied tissue leads to erratic glucose control.

The abdomen offers the most consistent absorption for subcutaneous GLP-1 receptor agonists. The thigh is second. The upper arm is acceptable but requires another person to administer. Within each region, shift the injection point at least 1 inch from the previous week's site.

A practical rotation schedule: divide your abdomen into four quadrants (upper-left, upper-right, lower-left, lower-right) and cycle through them over four weeks. On week five, switch to the right thigh. Week six, left thigh. This six-week rotation ensures no single site is used more than once in a 42-day period.

Do not inject into skin that is bruised, tender, scarred, or hard. Avoid areas with stretch marks or active skin conditions.

How Dulaglutide Works: Mechanism of Action

Dulaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone glucagon-like peptide-1, which the gut releases after eating. The molecule consists of two modified GLP-1 analogue chains fused to a modified human IgG4 Fc fragment, giving it a half-life of approximately 5 days and enabling once-weekly dosing 5.

Three actions produce its glucose-lowering effect. First, dulaglutide stimulates glucose-dependent insulin secretion from pancreatic beta cells. "Glucose-dependent" is the critical qualifier: the drug prompts insulin release only when blood glucose is elevated, which substantially lowers hypoglycemia risk compared to sulfonylureas 1. Second, it suppresses glucagon secretion from alpha cells during hyperglycemia. Third, it slows gastric emptying, reducing the postprandial glucose spike.

The REWIND trial (N=9,901), published in The Lancet in 2019, demonstrated that dulaglutide 1.5 mg once weekly reduced major adverse cardiovascular events (MACE) by 12% compared to placebo over a median follow-up of 5.4 years (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) 6. This result was notable because 69% of participants had no prior cardiovascular disease at enrollment, making REWIND one of the few GLP-1 RA trials to show primary prevention benefit.

Dr. Hertzel Gerstein, principal investigator of REWIND and professor of medicine at McMaster University, stated: "The cardiovascular benefit of dulaglutide was consistent across subgroups, including those without established cardiovascular disease, which distinguishes this trial from earlier GLP-1 receptor agonist cardiovascular outcomes studies" 6.

Common Injection Errors and How to Avoid Them

Even with a simplified autoinjector, technique errors occur. A post-marketing survey of 382 Trulicity users published in Diabetes Therapy identified five recurring mistakes 7.

Lifting the pen too early. This is the most frequent error (reported by 8.4% of users). If you lift before the second click or before the 10-second count, a partial dose may be delivered. The gray button will not fully lock down if the injection is incomplete. You cannot re-inject with the same pen; contact your prescriber for guidance.

Injecting through clothing. The pen is designed for bare-skin use. Fabric can block the needle from fully extending, resulting in subcutaneous misdelivery or an intramuscular injection.

Failing to press firmly enough. The pen requires firm, sustained pressure to activate the needle mechanism. Light or angled contact may trigger the click sound without proper needle insertion. Keep the base flush against the skin.

Using an expired or improperly stored pen. Dulaglutide degrades when exposed to temperatures above 30°C or direct sunlight. The Endocrine Society's 2024 clinical practice guideline on injectable therapies recommends patients verify storage conditions at each injection 8.

Skipping site rotation. As noted above, repeated injection into the same spot leads to lipohypertrophy. Patients often default to the same site out of habit. Setting a phone reminder with the next injection site is simple and effective.

Managing Injection-Site Reactions

Injection-site reactions (ISRs) occurred in 0.5% to 2.1% of dulaglutide-treated patients across the AWARD clinical trial program, compared to 0% to 0.5% with placebo 1. The most common ISRs are erythema (redness), pruritus (itching), and induration (hardness) at the injection site. These are typically mild and resolve without intervention within 48 hours.

If redness persists beyond 72 hours, expands in diameter, or is accompanied by warmth and increasing pain, evaluate for infection. True cellulitis at GLP-1 RA injection sites is rare but reported.

Applying a cold pack for 5 to 10 minutes before injection may reduce discomfort. Allowing the pen to reach full room temperature before use is more effective at reducing pain than applying ice afterward. A randomized crossover study of 52 patients using subcutaneous autoinjectors found that room-temperature injection reduced pain scores by 31% on a visual analog scale compared to refrigerator-temperature injection 9.

Dose Titration and Pen Identification

Trulicity is available in four dose strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Each strength has a distinct pen color to prevent dosing errors.

| Dose | Pen Color | Typical Use | |------|-----------|-------------| | 0.75 mg | Light green | Starting dose | | 1.5 mg | Dark green | First escalation, REWIND trial dose | | 3.0 mg | Yellow | Second escalation | | 4.5 mg | Red | Maximum approved dose |

The FDA-approved titration schedule begins at 0.75 mg weekly, with an increase to 1.5 mg after at least 4 weeks if additional glycemic control is needed. Further increases to 3.0 mg and then 4.5 mg follow the same 4-week minimum interval 1. The AWARD-11 trial (N=1,842) demonstrated that the 3.0 mg and 4.5 mg doses produced greater HbA1c reductions than 1.5 mg (1.71% and 1.87% vs. 1.54% from baseline, respectively; P<0.001 for both comparisons) 10.

Dr. Juan Frias, principal investigator of AWARD-11, noted: "The higher doses of dulaglutide provided meaningful incremental glycemic benefit with a safety profile consistent with the GLP-1 receptor agonist class" 10.

Always verify that the pen color and labeled dose match your prescription before injecting.

Traveling and Storing the Pen

Dulaglutide pens should be refrigerated at 2°C to 8°C (36°F to 46°F) until use. They may be kept at room temperature (up to 30°C / 86°F) for a single period of up to 14 days. Once a pen has been at room temperature for 14 days, it must be discarded even if unused 1.

For air travel, pack pens in a carry-on bag with an insulated pouch and a gel ice pack. Checked baggage holds can drop below freezing. Frozen dulaglutide must not be used. The American Diabetes Association's travel guidelines recommend carrying a copy of your prescription and a letter from your prescriber when traveling internationally with injectable medications 11.

TSA allows injectable medications and sharps disposal containers through security with proper labeling. You do not need to declare the pen separately, but keeping it in its original pharmacy-labeled carton speeds the screening process.

When to Contact Your Prescriber

Contact your prescriber if you experience any of the following after injection: severe abdominal pain that radiates to the back (possible pancreatitis, reported in 0.1% of trial participants) 1; a lump at the injection site that does not resolve within two weeks; signs of allergic reaction including facial swelling, difficulty breathing, or widespread rash; or persistent nausea and vomiting lasting more than 72 hours after dose escalation.

If you believe you received a partial dose because the gray button did not lock down, do not attempt a second injection with a new pen without medical guidance. Your prescriber may instruct you to re-dose or wait until the next scheduled injection depending on the estimated delivered amount.

Report pen malfunctions to Eli Lilly's medical information line (1-800-545-5979) and to the FDA's MedWatch program. Device malfunction reports are tracked through the Manufacturer and User Facility Device Experience (MAUDE) database 12.